Brief: Aeon Biopharma Reports bpd Type 2A Meeting With FDA And Shareholder Approval Of The November Transactions
21/01/2026 21:40
Jan 21 (Reuters) - Aeon Biopharma Inc AEON.A: AEON BIOPHARMA REPORTS BPD TYPE 2A MEETING WITH FDA AND SHAREHOLDER APPROVAL OF THE NOVEMBER TRANSACTIONS Source text: ID:nGNXbnbqJl Further company coverage: AEON.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aeon Biopharma
See all newsBrief: Aeon Biopharma Reports bpd Type 2A Meeting With FDA And Shareholder Approval Of The November Transactions
Brief: Aeon Biopharma Announces Execution Of Exchange Agreement With Daewoong
Brief: Aeon Biopharma Announces First Closing Of Pipe Investment And Provides Update On FDA Type 2A Meeting Scheduling
Brief: Aeon Biopharma Announces FDA bpd Type 2A Meeting For Abp-450 On November 19
Brief: Aeon Biopharma Announces CEO Transition